A GSK3-binding peptide from FRAT1 selectively inhibits the GSK3-catalysed phosphorylation of axin and beta-catenin
about
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNSGSK-3β: A Bifunctional Role in Cell Death PathwaysThe kinase DYRK phosphorylates protein-synthesis initiation factor eIF2Bepsilon at Ser539 and the microtubule-associated protein tau at Thr212: potential role for DYRK as a glycogen synthase kinase 3-priming kinaseThe low density lipoprotein receptor-related protein 6 interacts with glycogen synthase kinase 3 and attenuates activityI-mfa domain proteins interact with Axin and affect its regulation of the Wnt and c-Jun N-terminal kinase signaling pathways.Direct inhibition of GSK3beta by the phosphorylated cytoplasmic domain of LRP6 in Wnt/beta-catenin signalingGlycogen synthase kinase 3: more than a namesakeDisrupted in schizophrenia 1 regulates neuronal progenitor proliferation via modulation of GSK3beta/beta-catenin signalingGlycogen synthase kinase 3: a point of convergence for the host inflammatory responseGSK-3: tricks of the trade for a multi-tasking kinaseTissue microarray analysis of human FRAT1 expression and its correlation with the subcellular localisation of beta-catenin in ovarian tumoursDistinct priming kinases contribute to differential regulation of collapsin response mediator proteins by glycogen synthase kinase-3 in vivoGlycogen Synthase Kinase-3 (GSK-3)-Targeted Therapy and ImagingCurrent Understanding on EGFR and Wnt/β-Catenin Signaling in Glioma and Their Possible CrosstalkGSK3β and the control of infectious bacterial diseasesStructural basis for recruitment of glycogen synthase kinase 3beta to the axin-APC scaffold complexAxin-dependent phosphorylation of the adenomatous polyposis coli protein mediated by casein kinase 1epsilonMood stabilizers, glycogen synthase kinase-3beta and cell survivalFRAT-2 preferentially increases glycogen synthase kinase 3 beta-mediated phosphorylation of primed sites, which results in enhanced tau phosphorylationLight and electron microscopy study of glycogen synthase kinase-3beta in the mouse brainGlycogen synthase kinase 3beta-mediated apoptosis of primary cortical astrocytes involves inhibition of nuclear factor kappaB signalingA divergent canonical WNT-signaling pathway regulates microtubule dynamics: dishevelled signals locally to stabilize microtubulesGSK-3: Functional Insights from Cell Biology and Animal Models.Expression and characterization of GSK-3 mutants and their effect on beta-catenin phosphorylation in intact cells.Glucose regulates steady-state levels of PDX1 via the reciprocal actions of GSK3 and AKT kinasesMechanism and function of signal transduction by the Wnt/beta-catenin and Wnt/Ca2+ pathways.Oncogenic mutants of RON and MET receptor tyrosine kinases cause activation of the beta-catenin pathway.Testosterone prevents the heat shock-induced overactivation of glycogen synthase kinase-3 beta but not of cyclin-dependent kinase 5 and c-Jun NH2-terminal kinase and concomitantly abolishes hyperphosphorylation of tau: implications for Alzheimer's dReadily accessible bicyclononynes for bioorthogonal labeling and three-dimensional imaging of living cells.Prediction of the binding mode between GSK3β and a peptide derived from GSKIP using molecular dynamics simulation.Functional studies of shaggy/glycogen synthase kinase 3 phosphorylation sites in Drosophila melanogaster.Wingless-type frizzled protein receptor signaling and its putative role in human colon cancer.GSK3 takes centre stage more than 20 years after its discovery.FRAT1, a substrate-specific regulator of glycogen synthase kinase-3 activity, is a cellular substrate of protein kinase A.GSK-3 modulates cellular responses to a broad spectrum of kinase inhibitorsThe Wnt signaling pathway in bipolar disorder.Bioinformatic prediction and confirmation of beta-adducin as a novel substrate of glycogen synthase kinase 3.Challenges and opportunities with glycogen synthase kinase-3 inhibitors for insulin resistance and Type 2 diabetes treatment.MicroRNA-149*, a p53-responsive microRNA, functions as an oncogenic regulator in human melanomaGenome-wide microarray expression and genomic alterations by array-CGH analysis in neuroblastoma stem-like cells.
P2860
13124ac963b2f70949c63a8f57397c63e959463e57fc31698d74194c1b520e4e39feeccbfadafd825c73d181ada52761510b9056fb17d1690b7712cb8dfad928308f342e16835075220cf114c4bf002c9b35834b52b0de223845cc293b20190877b0d5e1aa648bb89628aba98b1c9cdb13ff2e19ff2740b6c163ad5b15d92770f0ec51ab0e97c4684fdcf6b3e39e714560686919e7bb68f51ea6b4ebb593e267
P248
Q21129334-CB7029FF-D562-43E4-81C7-CE40EDD296F1Q21285144-294EB075-ADDD-48FA-9CD9-3C8A2C550DBAQ24291138-EA1B95CF-765D-4487-BAB6-0B59D5D57596Q24299312-1F899DC5-DDBB-41EC-B2EC-8483B6187606Q24305168-791202BB-725B-4315-8A95-C4919C617001Q24310506-6413F617-B54A-4305-8A8B-54C350024840Q24315635-85003F0C-54CA-4296-8D4D-D50F89242930Q24322974-DAFC9E8B-4BF2-4550-8162-5D7FC9209CFFQ24597129-51B4624D-7F0C-4227-961A-154AAA5094A9Q24624069-A2C45CD1-F37E-41AF-A139-74261448BDCCQ24651981-307435AD-14F4-47F9-A368-62E470147851Q24685647-48F5FF37-6673-4463-B67F-7DF2522D0538Q26768475-86A3F8FC-608A-499A-9702-874788902B4BQ26865911-88887DAA-00C7-488C-8E10-C05DDC24C214Q27013766-BF9412D3-E3A3-4347-A75A-16D7EA1D9DF1Q27640372-C16214F1-2353-41C3-8BE9-560F8E37E76BQ28211035-0AA961B7-C522-4D13-8918-ABB0231B1B01Q28216404-462E5D03-3B7C-4B77-90E1-3711B499C55FQ28291371-695716FA-A31F-4B8A-BDE3-534C51C9FC9EQ28472669-9DAD53B2-6C64-4556-B6EC-38F08BB636EFQ28581844-22EA2C43-BB74-4F75-B93C-443322AD4241Q28586223-DF438A82-B64D-4BDB-B682-7403B85061FDQ30472813-A8CB0824-1E38-4ACD-A8FA-0F6D913FBDB9Q33183622-0FB75655-47BC-47CD-98A9-3A33C0B90169Q33661627-EBA55B33-394E-4339-9EA0-6BA3485D2C65Q33814311-6FEB2377-1D42-48BF-9FC4-3F8F4298F3E7Q33969327-A44C8963-A2DA-42F2-BBA0-71E4174F7DCBQ34008372-0C2F74B7-3BAC-4D25-9ADE-EF1CEDDC0DBBQ34139183-59D72300-DFB8-4DA2-B3F4-27E296F4A11BQ34165161-C0C63DC2-7698-4847-BCA7-CC6A3A1F4135Q34180579-DCAB9DC3-2E28-4BCD-8747-76DD4F4C58EEQ34277243-45D7C274-C55C-487B-AFD2-0F5C89C68DDAQ34374129-E99776B9-1F0A-4134-AB28-AD3EEB57CBDAQ34566865-AD15D593-EAB8-46D6-9918-BA94C11BA151Q34735363-51292621-2197-47B8-9718-DEB2A81D5B4FQ34956351-42E6A3F0-8C71-4F5F-8B65-AC6D6610B6A7Q35107567-45E79E07-426B-4BCB-AD7C-71A3A745E81FQ35207622-C2DEABB5-0CC1-4304-8EBF-C5723A5BC8A8Q35229253-D26E6156-6BED-42DF-9493-36DF03525B0CQ35416653-F666BFF7-AF89-4E31-9310-3B26A17BFC79
P2860
A GSK3-binding peptide from FRAT1 selectively inhibits the GSK3-catalysed phosphorylation of axin and beta-catenin
description
1999 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 1999
@ast
im September 1999 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 1999/09/17)
@sk
vědecký článek publikovaný v roce 1999
@cs
wetenschappelijk artikel (gepubliceerd op 1999/09/17)
@nl
наукова стаття, опублікована у вересні 1999
@uk
مقالة علمية (نشرت في 17-9-1999)
@ar
name
A GSK3-binding peptide from FR ...... ation of axin and beta-catenin
@ast
A GSK3-binding peptide from FR ...... ation of axin and beta-catenin
@en
A GSK3-binding peptide from FR ...... ation of axin and beta-catenin
@nl
type
label
A GSK3-binding peptide from FR ...... ation of axin and beta-catenin
@ast
A GSK3-binding peptide from FR ...... ation of axin and beta-catenin
@en
A GSK3-binding peptide from FR ...... ation of axin and beta-catenin
@nl
prefLabel
A GSK3-binding peptide from FR ...... ation of axin and beta-catenin
@ast
A GSK3-binding peptide from FR ...... ation of axin and beta-catenin
@en
A GSK3-binding peptide from FR ...... ation of axin and beta-catenin
@nl
P2093
P2860
P3181
P1433
P1476
A GSK3-binding peptide from FR ...... ation of axin and beta-catenin
@en
P2093
P2860
P304
P3181
P356
10.1016/S0014-5793(99)01161-8
P407
P577
1999-09-01T00:00:00Z